• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SARS-CoV-2 感染的实验模型。

Experimental Models for SARS-CoV-2 Infection.

机构信息

Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Korea.

These authors contributed equally to this work.

出版信息

Mol Cells. 2021 Jun 30;44(6):377-383. doi: 10.14348/molcells.2021.0094.

DOI:10.14348/molcells.2021.0094
PMID:34187969
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8245318/
Abstract

Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is a novel virus that causes coronavirus disease 2019 (COVID-19). To understand the identity, functional characteristics and therapeutic targets of the virus and the diseases, appropriate infection models that recapitulate the pathophysiology of the viral infection are necessary. This article reviews the various infection models, including Vero cells, human cell lines, organoids, and animal models, and discusses their advantages and disadvantages. This knowledge will be helpful for establishing an efficient system for defense against emerging infectious diseases.

摘要

严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)是一种新型病毒,可引起 2019 年冠状病毒病(COVID-19)。为了了解病毒和疾病的特性、功能和治疗靶点,需要建立能够重现病毒感染病理生理学的合适感染模型。本文综述了各种感染模型,包括 Vero 细胞、人细胞系、类器官和动物模型,并讨论了它们的优缺点。这些知识将有助于建立针对新发传染病的有效防御系统。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af50/8245318/db027383e6c2/molce-44-6-377-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af50/8245318/4748c16f8266/molce-44-6-377-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af50/8245318/db027383e6c2/molce-44-6-377-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af50/8245318/4748c16f8266/molce-44-6-377-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af50/8245318/db027383e6c2/molce-44-6-377-f2.jpg

相似文献

1
Experimental Models for SARS-CoV-2 Infection.SARS-CoV-2 感染的实验模型。
Mol Cells. 2021 Jun 30;44(6):377-383. doi: 10.14348/molcells.2021.0094.
2
Infection of bat and human intestinal organoids by SARS-CoV-2.新冠病毒感染蝙蝠和人类肠类器官。
Nat Med. 2020 Jul;26(7):1077-1083. doi: 10.1038/s41591-020-0912-6. Epub 2020 May 13.
3
Review of studies of severe acute respiratory syndrome related coronavirus-2 pathogenesis in human organoid models.人类类器官模型中严重急性呼吸综合征相关冠状病毒2发病机制的研究综述。
Rev Med Virol. 2021 Nov;31(6):e2227. doi: 10.1002/rmv.2227. Epub 2021 Mar 25.
4
Infectivity, virulence, pathogenicity, host-pathogen interactions of SARS and SARS-CoV-2 in experimental animals: a systematic review.实验动物中 SARS 和 SARS-CoV-2 的感染性、毒力、致病性、宿主-病原体相互作用:系统评价。
Vet Res Commun. 2020 Nov;44(3-4):101-110. doi: 10.1007/s11259-020-09778-9. Epub 2020 Jul 10.
5
Human Intestinal Organoids Recapitulate Enteric Infections of Enterovirus and Coronavirus.人类肠道类器官可重现肠道病毒和冠状病毒感染。
Stem Cell Reports. 2021 Mar 9;16(3):493-504. doi: 10.1016/j.stemcr.2021.02.009. Epub 2021 Feb 12.
6
An organoid-derived bronchioalveolar model for SARS-CoV-2 infection of human alveolar type II-like cells.类器官衍生的支气管肺泡模型用于 SARS-CoV-2 感染人肺泡 II 型样细胞。
EMBO J. 2021 Mar 1;40(5):e105912. doi: 10.15252/embj.2020105912. Epub 2021 Jan 11.
7
SARS-CoV-2 entry into human airway organoids is serine protease-mediated and facilitated by the multibasic cleavage site.SARS-CoV-2 进入人呼吸道类器官是丝氨酸蛋白酶介导的,并由多碱性裂解位点促进。
Elife. 2021 Jan 4;10:e64508. doi: 10.7554/eLife.64508.
8
Cross-validation of SARS-CoV-2 responses in kidney organoids and clinical populations.肾类器官和临床人群中 SARS-CoV-2 反应的交叉验证。
JCI Insight. 2021 Dec 22;6(24):e154882. doi: 10.1172/jci.insight.154882.
9
Human Nasal and Lung Tissues Infected with SARS-CoV-2 Provide Insights into Differential Tissue-Specific and Virus-Specific Innate Immune Responses in the Upper and Lower Respiratory Tract.人鼻腔和肺部组织感染 SARS-CoV-2 提供了在上呼吸道和下呼吸道中不同组织特异性和病毒特异性先天免疫反应的见解。
J Virol. 2021 Jun 24;95(14):e0013021. doi: 10.1128/JVI.00130-21.
10
SARS-CoV-2 evolution in animals suggests mechanisms for rapid variant selection.动物中的 SARS-CoV-2 进化表明了快速变异选择的机制。
Proc Natl Acad Sci U S A. 2021 Nov 2;118(44). doi: 10.1073/pnas.2105253118.

引用本文的文献

1
SARS-CoV-2 Spike S1 Subunit Triggers Pericyte and Microvascular Dysfunction in Human Pancreatic Islets.严重急性呼吸综合征冠状病毒2刺突蛋白S1亚基引发人胰岛中的周细胞和微血管功能障碍。
Diabetes. 2025 Mar 1;74(3):355-367. doi: 10.2337/db24-0816.
2
Recent advances and applications of human lung alveolar organoids.人肺肺泡类器官的最新进展与应用
Mol Cells. 2024 Dec;47(12):100140. doi: 10.1016/j.mocell.2024.100140. Epub 2024 Oct 28.
3
Why Certain Repurposed Drugs Are Unlikely to Be Effective Antivirals to Treat SARS-CoV-2 Infections.为何某些重新利用的药物不太可能成为治疗新冠病毒感染的有效抗病毒药物。

本文引用的文献

1
Application of human liver organoids as a patient-derived primary model for HBV infection and related hepatocellular carcinoma.人源肝类器官在 HBV 感染及相关肝细胞癌中的应用:患者来源的原发性模型。
Elife. 2021 Jul 30;10:e60747. doi: 10.7554/eLife.60747.
2
Single-cell transcriptome of bronchoalveolar lavage fluid reveals sequential change of macrophages during SARS-CoV-2 infection in ferrets.肺泡灌洗液单细胞转录组分析揭示 SARS-CoV-2 在雪貂体内感染过程中巨噬细胞的动态变化。
Nat Commun. 2021 Jul 27;12(1):4567. doi: 10.1038/s41467-021-24807-0.
3
Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model.
Viruses. 2024 Apr 22;16(4):651. doi: 10.3390/v16040651.
4
Immune Responses and Pathogenesis following Experimental SARS-CoV-2 Infection in Domestic Cats.实验性 SARS-CoV-2 感染家猫后的免疫反应和发病机制。
Viruses. 2023 Apr 25;15(5):1052. doi: 10.3390/v15051052.
5
Microgliosis and neuronal proteinopathy in brain persist beyond viral clearance in SARS-CoV-2 hamster model.在 SARS-CoV-2 仓鼠模型中,病毒清除后,脑内小胶质细胞增生和神经元蛋白病变仍然存在。
EBioMedicine. 2022 May;79:103999. doi: 10.1016/j.ebiom.2022.103999. Epub 2022 Apr 16.
6
Air-Liquid-Interface Differentiated Human Nose Epithelium: A Robust Primary Tissue Culture Model of SARS-CoV-2 Infection.气液界面分化的人鼻上皮细胞:一种 SARS-CoV-2 感染的稳健原代组织培养模型。
Int J Mol Sci. 2022 Jan 13;23(2):835. doi: 10.3390/ijms23020835.
7
Scientific Understanding of COVID-19: The First Step to Vanquishing the Current Pandemic.对新冠病毒的科学认知:战胜当前疫情的第一步。
Mol Cells. 2021 Jun 30;44(6):375-376. doi: 10.14348/molcells.2021.0146.
法匹拉韦对仓鼠模型中 SARS-CoV-2 的抗病毒疗效。
Nat Commun. 2021 Mar 19;12(1):1735. doi: 10.1038/s41467-021-21992-w.
4
Development of Spike Receptor-Binding Domain Nanoparticles as a Vaccine Candidate against SARS-CoV-2 Infection in Ferrets.棘突受体结合域纳米颗粒的研制作为针对 SARS-CoV-2 感染的疫苗候选物在雪貂中的应用。
mBio. 2021 Mar 2;12(2):e00230-21. doi: 10.1128/mBio.00230-21.
5
Transcriptomic profiling of SARS-CoV-2 infected human cell lines identifies HSP90 as target for COVID-19 therapy.对感染SARS-CoV-2的人类细胞系进行转录组分析确定HSP90为COVID-19治疗靶点。
iScience. 2021 Mar 19;24(3):102151. doi: 10.1016/j.isci.2021.102151. Epub 2021 Feb 6.
6
Genetic Screens Identify Host Factors for SARS-CoV-2 and Common Cold Coronaviruses.遗传筛选鉴定 SARS-CoV-2 和普通感冒冠状病毒的宿主因子。
Cell. 2021 Jan 7;184(1):106-119.e14. doi: 10.1016/j.cell.2020.12.004. Epub 2020 Dec 9.
7
Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets.治疗性给予核苷类似物 MK-4482/EIDD-2801 可阻断雪貂体内的 SARS-CoV-2 传播。
Nat Microbiol. 2021 Jan;6(1):11-18. doi: 10.1038/s41564-020-00835-2. Epub 2020 Dec 3.
8
Establishment of an African green monkey model for COVID-19 and protection against re-infection.建立用于 COVID-19 的非洲绿猴模型并预防再感染。
Nat Immunol. 2021 Jan;22(1):86-98. doi: 10.1038/s41590-020-00835-8. Epub 2020 Nov 24.
9
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.一项在 18-59 岁健康成年人中进行的新型冠状病毒灭活疫苗的安全性、耐受性和免疫原性的随机、双盲、安慰剂对照、1/2 期临床试验。
Lancet Infect Dis. 2021 Feb;21(2):181-192. doi: 10.1016/S1473-3099(20)30843-4. Epub 2020 Nov 17.
10
Three-Dimensional Human Alveolar Stem Cell Culture Models Reveal Infection Response to SARS-CoV-2.三维人肺泡干细胞培养模型揭示了对 SARS-CoV-2 的感染反应。
Cell Stem Cell. 2020 Dec 3;27(6):905-919.e10. doi: 10.1016/j.stem.2020.10.004. Epub 2020 Oct 21.